The Dominantly Inherited Alzheimer Network Expanded Registry (DIAN EXR) is an international research registry for individuals with confirmed or suspected dominantly inherited Alzheimer’s disease (DIAD) in their families and for professionals and researchers involved in clinical care and research on DIAD.
Individuals & Families
Join the DIAN Expanded Registry
Your participation and collaboration help to advance both the understanding and treatment of DIAD. Your enrollment will determine your eligibility for DIAD research studies and clinical trials.
Researchers & Health Professionals
Join the DIAN Expanded Registry
We invite physicians, researchers, genetic counselors and other health professionals so that they can be a part of DIAN-TU and/or DIAN research as a participating research site, as well as refer their patients to DIAN-TU/DIAN research studies.
Who is eligible?
Individuals and family members affected by the disease or those who suspect they are affected. You are eligible to enroll in the Registry if you are aged 18 or older and have at least two generations of family members who have experienced symptoms consistent with Alzheimer’s disease before the age of 60. You do not need to know whether you yourself carry a gene mutation that causes Alzheimer’s disease.
Physicians, researchers, genetic counselors and other health professionals who have research interests in DIAD and/or provide care for family members affected by DIAD.
Benefits of joining
- Learn about current research and clinical trials
- Make themselves available as a potential clinical trial participants
- Gain access to genetic counseling and testing as part of an ongoing research project
- Attend international family conferences and engage in other educational opportunities
- Receive regular updates about upcoming events and resources
- Identify potential clinical trial participants
- Find collaborators
Information in the Registry is kept strictly confidential and is securely stored. At any time, you may contact us to remove your information.
The Registry is managed by the DIAN Trials Unit (DIAN-TU) at Washington University School of Medicine in St. Louis. It is funded in part by grants from the Alzheimer’s Association, a consortium of pharmaceutical companies and philanthropic foundations. The Director of the DIAN EXR is Eric McDade, DO.